Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:34:26 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Q:SNY - SANOFI SPON ADR ECH REP 0.5 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SNY - Q1.623.62·44.050.243.88-1.14-2.51,879.381,68112,60944.41  44.58  43.8552.68  42.2819:05:04May 0615 min RT 2¢

Recent Trades - Last 10 of 12609
Time ETExPriceChangeVolume
19:05:04Q43.88-1.14200
18:50:44Q43.8254-1.194611
18:05:37Q44.0188-1.00124
17:20:31Q43.88-1.14160,651
16:50:41Q43.88-1.1443,659
16:35:55Q43.88-1.141
16:17:31Q43.88-1.141,901
16:10:04Q43.88-1.141
16:10:04Q43.88-1.141
16:04:49Q43.88-1.141

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-06 12:41U:SNYNews ReleaseSanofi Supports AlphaDetect to Accelerate Detection of Alpha-1
2026-05-04 13:00U:SNYNews ReleaseSanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patients
2026-04-22 17:30U:SNYNews ReleaseDupixent(TM) (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
2026-04-09 10:00U:SNYNews ReleaseSanofi becomes market authorization holder for Nuvaxovid(TM) in Canada, expanding COVID-19 vaccine choices for Canadians
2026-03-24 02:00U:SNYNews ReleaseDupixent(TM) (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
2026-02-17 08:30U:SNYNews ReleaseSanofi announces leadership evolution in Specialty Care Business Unit
2026-02-03 08:00U:SNYNews ReleaseRezurock(TM) now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (GVHD)
2025-12-23 01:00U:SNYNews ReleaseDupixent(TM) (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
2025-11-25 01:00U:SNYNews ReleaseDupixent(TM) (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
2025-10-27 20:48U:SNYNews ReleaseUPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
2025-10-23 01:00U:SNYNews ReleaseSanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
2025-10-21 13:52U:SNYNews Release/C O R R E C T I O N -- Sanofi-Aventis Canada Inc./
2025-10-16 06:00U:SNYNews ReleaseEVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
2025-09-26 08:00U:SNYNews ReleaseSanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
2025-09-22 00:29U:SNYNews ReleaseDupixent(TM) (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
2025-09-10 08:00U:SNYNews ReleaseMandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS(TM)
2025-08-26 11:00U:SNYNews ReleaseNew Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week
2025-07-22 11:57U:SNYNews ReleaseBEYFORTUS(TM) reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study
2025-06-26 08:00U:SNYNews ReleaseSanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
2025-06-15 11:21U:SNYNews ReleaseDupixent(TM) (dupilumab) Demonstrated Superiority Over Xolair(TM) (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial